枸橼酸伊沙佐米(Ixazomib citrate) - 药物靶点：Proteasome_在研适应症：多发性骨髓瘤，复发性浆细胞骨髓瘤，难治性多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ixazomib、Ixazomib citrate (JAN/USAN)、伊沙佐米

+ [8]

靶点

Proteasome

作用方式

抑制剂

作用机制

蛋白酶体抑制剂

治疗领域

肿瘤免疫系统疾病心血管疾病+ [4]

在研适应症

多发性骨髓瘤复发性浆细胞骨髓瘤难治性多发性骨髓瘤+ [22]

非在研适应症

急性双表型白血病急性白血病急性髓性白血病+ [26]

原研机构

Millennium Pharmaceuticals, Inc.

在研机构

Takeda Pharma SA

Takeda Pharmaceutical Co., Ltd.Haupt Pharma Amareg GmbH

+ [10]

非在研机构

Medical College of WisconsinTakeda Pharmaceuticals International, Inc.

Bristol Myers Squibb Co.

最高研发阶段批准上市

首次获批日期

美国 (2015-11-20),

多发性骨髓瘤

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、特殊审批 (中国)、孤儿药 (韩国)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C20H23BCl2N2O9

InChIKeyMBOMYENWWXQSNW-AWEZNQCLSA-N

CAS号1239908-20-3

关联

188

项与枸橼酸伊沙佐米相关的临床试验

CTR20250336

/ RecruitingN/A

枸橼酸伊沙佐米胶囊在肿瘤患者空腹状态下随机、开放、两周期、两交叉生物等效性研究

评价正大天晴药业集团股份有限公司提供的枸橼酸伊沙佐米胶囊（4mg）和Takeda Pharma A/S持证的枸橼酸伊沙佐米胶囊（恩莱瑞®）（4mg）在空腹状态下给药的人体生物等效性；观察受试制剂枸橼酸伊沙佐米胶囊（4mg，正大天晴药业集团股份有限公司）和参比制剂枸橼酸伊沙佐米胶囊（恩莱瑞®）（4mg，Takeda Pharma A/S持证）在肿瘤患者中的安全性.

开始日期2025-02-27

申办/合作机构

正大天晴药业集团股份有限公司

CTR20243959

/ TerminatedN/A

枸橼酸伊沙佐米胶囊人体生物等效性研究

本试验旨在研究单次空腹口服杭州中美华东制药有限公司研制、生产的枸橼酸伊沙佐米胶囊（4 mg）的药代动力学特征；以Takeda Pharma A/S持证、Haupt Pharma Amareg GmbH生产的枸橼酸伊沙佐米胶囊（恩莱瑞®，4 mg）为参比制剂，比较两制剂中药动学参数Cmax和AUC0-72，评价两制剂的人体生物等效性。

开始日期2024-10-28

申办/合作机构

杭州中美华东制药有限公司

CTR20241457

/ RecruitingN/A

枸橼酸伊沙佐米胶囊在中国多发性骨髓瘤患者中空腹单剂量口服给药的生物等效性试验

主要研究目的：观察中国多发性骨髓瘤患者空腹单剂量口服枸橼酸伊沙佐米胶囊（规格：4 mg/粒，江苏天士力帝益药业有限公司生产）后的药物体内代谢过程，以恩莱瑞®（规格：4 mg/粒，Takeda Pharma A/S生产）为参比制剂，以药代动力学参数为终点指标，评价空腹状态下口服两种制剂的生物等效性。次要研究目的：观察枸橼酸伊沙佐米胶囊在中国多发性骨髓瘤患者中的安全性。

开始日期2024-05-31

申办/合作机构

江苏天士力帝益药业有限公司

100 项与枸橼酸伊沙佐米相关的临床结果

登录后查看更多信息

100 项与枸橼酸伊沙佐米相关的转化医学

登录后查看更多信息

100 项与枸橼酸伊沙佐米相关的专利（医药）

登录后查看更多信息

1,040

项与枸橼酸伊沙佐米相关的文献（医药）

2025-03-01·SUPPORTIVE CARE IN CANCER

Proteasome inhibitor-associated thrombotic microangiopathy: a real-world retrospective and pharmacovigilance database analysis

Article

作者: Wang, Chunjiang ; Wang, Shengfeng ; Deng, Zhenzhen

OBJECTIVES:

Thrombotic microangiopathy (TMA) is associated with carfilzomib, but the potential association between bortezomib or ixazomib exposure and TMA is still unknown. Besides, the knowledge of carfilzomib-induced TMA is based mainly on case reports. We aim to quantify the risk and better characterize the clinical features of proteasome inhibitor (PI)-induced TMA.

METHODS:

Data from 2004 to 2023 on TMA events induced by PIs were retrieved from the FDA Adverse Event Reporting System (FAERS) database and conducted disproportionality analyse. Case reports/series from 2004 to 2023 on PI-induced TMA were extracted and analyzed retrospectively.

RESULTS:

FAERS pharmacovigilance data identified 225 TMA cases across 213 individuals related to PIs therapy. PIs were significantly associated with TMA (n = 213, ROR 1.71 [1.49-1.96]; EBGM 1.70 [1.52]), and carfilzomib had the greatest proportion (58.7%) and highest positive signal values (n = 125, ROR 17.97 [15.04-21.47]; EBGM 17.49 [15.07]) of TMA. Sixty cases (median age: 63 years) from 35 studies showed evidence of TMA, with 37 (61.7%) were male. The typical initial symptoms were gastrointestinal symptoms (45.3%), fever (24.5%), fatigue/asthenia (20.8%), neurological signs (18.9%), and dyspnea (17.0%). The median time to TMA onset was 8 days. Most patients presented with hemolytic anemia (98.1%), thrombocytopenia (96.6%), and acute kidney injury (96.7%). Cessation of PIs and treatment with plasma exchange therapy (25.0%), hemodialysis (31.7%), and eculizumab (26.7%) were associated with improved hematologic outcomes (96.3%) and renal outcomes (93.3%).

CONCLUSION:

This study identified PIs agents with significant reporting associations with TMA. A prompt diagnosis of TMA and supportive treatments are necessary for patients receiving PIs concurrent with anemia, thrombocytopenia, and acute kidney injury.

2025-03-01·YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Evaluation of Ixazomib Relative Dose Intensity for IRd Therapy in Elderly Patients with Relapsed or Refractory Multiple Myeloma: A Preliminary Study

Article

作者: Sugiyama, Tomoki ; Kanda, Tomoe ; Usami, Eiseki ; Takenaka, Shoya ; Kimura, Michio ; Hirose, Tatsuya

Ixazomib (IXA) is a convenient oral anticancer drug; however, due to its fixed dosage, IXA tolerability among elderly Japanese individuals may be reduced. Therefore, this study aimed to clarify the difference in relative dose intensity (RDI) of IXA in IRd therapy in elderly patients. Between October 2018 and September 2023, patients who underwent IRd therapy (IXA, lenalidomide, and dexamethasone combination treatment) at Ogaki Municipal Hospital were enrolled in the study and categorized into two age groups: ≥75 years (group O, n=16) and <75 years (group Y, n=6). We retrospectively analyzed RDI of IXA, in IRd therapy. In addition, we evaluated the reasons for dose reduction or delayed treatment. The median initial IXA dose was 3 mg (range: 2.3-4 mg) and 4 mg (range: 3-4 mg) in group O and Y, respectively (p=0.122). The median RDI in group O (65.8%, range: 51.1-91.7%) was significantly lower than in group Y (93.3%, range: 80.5-100.0%) (p=0.002). Among them, anorexia was more common in group O than in group Y (p=0.049). In group O, dose adjustments were made due to anorexia (n=10), diarrhea (n=5), nausea (n=2), and fatigue (n=2). In group Y, adjustments were made due to diarrhea (n=2) and thrombocytopenia (n=1). Upon IXA (4 mg) administration, the rate of dose adjustments due to gastrointestinal symptoms were 75% and 17% in group O and Y, respectively (p=0.051). Overall, RDI was lower in group O owing to gastrointestinal symptoms. This suggests that the fixed IXA dosage (4 mg) is less tolerable in older individuals.

2025-03-01·JOURNAL OF EUKARYOTIC MICROBIOLOGY

Effect of protease inhibitors on the intraerythrocytic development of Babesia microti and Babesia duncani, the causative agents of human babesiosis

Article

作者: Aderanti, Temitope ; Marshall, Jordan M. ; Thekkiniath, Jose

Abstract:

Human babesiosis is a malaria‐like, tick‐borne infectious disease with a global distribution. Babesiosis is caused by intraerythrocytic, apicomplexan parasites of the genus Babesia. In the United States, human babesiosis is caused by Babesia microti and Babesia duncani. Current treatment for babesiosis includes either the combination of atovaquone and azithromycin or the combination of clindamycin and quinine. However, the side effects of these agents and the resistance posed by these parasites call for alternative approaches for treating human babesiosis. Proteases play several roles in the context of parasitic lifestyle and regulate basic biological processes including cell death, cell progression, and cell migration. Using the SYBR Green‐1 assay, we screened a protease inhibitor library that consisted of 160 compounds against B. duncani in vitro and identified 13 preliminary hits. Dose response assays of hit compounds against B. duncani and B. microti under in vitro conditions identified five effective inhibitors against parasite growth. Of these compounds, we chose ixazomib, a proteasome inhibitor as a potential drug for animal studies based on its lower IC50 and a higher therapeutic index in comparison with other compounds. Our results suggest that Babesia proteasome may be an important drug target and that developing this class of drugs may be important to combat human babesiosis.

88

项与枸橼酸伊沙佐米相关的新闻（医药）

2025-02-26

·PipelineReview

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma

HEFEI, China I February 25, 2025 I Kangpu Biopharmaceuticals, Ltd. (“Kangpu”) today announced that the Company has received IND approval from the CDE (Center for Drug Evaluation) of China National Medical Products Administration (NMPA) for KPG-818 for the treatment of relapsed/refractory multiple myeloma (RRMM). KPG-818 is a novel oral molecular glue modulator of the E3 ubiquitin ligase complex CRL4-CRBN. It demonstrated high cereblon (CRBN) binding affinity and potent degradation of Aiolos (IKZF3) and Ikaros (IKZF1), two members of the Ikaros family of zinc-finger transcription factors associated with B-cell development. KPG-818 possesses immunomodulatory, anti-angiogenic, and anti-tumor effects. The Phase I clinical trial of KPG-818 in the United States for the treatment of various hematological tumors has been completed. Preliminary results indicate that in RRMM patients who have previously received two immunomodulatory drugs (lenalidomide and pomalidomide), at least one proteasome inhibitor (bortezomib, ixazomib, or carfilzomib), and a CD38 monoclonal antibody (daratumumab or isatuximab), KPG-818 demonstrated good safety, tolerability, pharmacokinetic characteristics, and encouraging therapeutic effects. About Kangpu Biopharmaceuticals Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative therapeutics for the treatment of solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders through novel solutions, including targeted protein degradation. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES ® , gDACs ® , and X-SYNERGY ® . For more information, please visit www.KangpuGroup.com . SOURCE: Kangpu Biopharmaceuticals

临床1期临床申请临床结果免疫疗法临床2期

2025-02-25

·E药经理人

康朴生物医药KPG-818治疗复发或难治多发性骨髓瘤在中国获批临床

中国合肥，2025年2月25日 -- 康朴生物医药技术（合肥）有限公司（“康朴生物医药”）今日宣布，公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意KPG-818胶囊开展用于治疗复发或难治多发性骨髓瘤（RRMM）的临床试验。 KPG-818是康朴生物医药设计开发的具有全球自主知识产权的新一代口服分子胶免疫调节药物，属于1类小分子新药。KPG-818归属E3泛素连接酶复合物CRL4-CRBN调节剂，对靶点CRBN显示出极高的亲和力，可以高效降解锌指转录因子Aiolos（IKZF3）和Ikaros（IKZF1），具有免疫调节、抗血管生成和抗肿瘤作用。 KPG-818在美国开展的治疗多种血液肿瘤的 Ⅰ 期临床试验已经结束，初步结果显示，在既往接受过两个度胺类药物（来那度胺和泊马度胺）、至少1个蛋白酶抑制剂（硼替佐米、伊沙佐米或卡非佐米）及一个CD38单抗（达雷妥尤单抗或艾沙妥昔单抗）的难治或复发末线多发性骨髓瘤患者中展现了良好的安全性、耐受性、药代动力学特征以及令人鼓舞的治疗效果。关于康朴生物医药总部位于安徽省合肥市的康朴生物医药是一家处于临床阶段的创新型生物医药企业。公司拥有一支实力雄厚、具有国际化视野和行业经验的创新药开发资深专家团队及运营团队。立足创新驱动，聚焦自身免疫疾病、癌症、炎症等治疗领域，康朴生物医药以国际领先的分子胶-蛋白质泛素化降解技术NeoMIDES®和gDACs®、X-SYNERGY®等自主专利技术为基础，致力于开发面向全球、具有全球自主知识产权的创新药物。为征服疾病、增进人类生命健康贡献力量。关于公司的更多信息，请浏览www.KangpuGroup.com 一审| 黄佳二审| 李芳晨三审| 李静芝

临床1期蛋白降解靶向嵌合体引进/卖出

2025-02-24

·摩熵医药

9亿+抗病毒制剂，齐鲁制药抢国内首仿！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 2月22日，据CDE官网显示，齐鲁制药（海南）提交的4类仿制药马立巴韦片上市申请获受理。马立巴韦片为抗病毒制剂，据摩熵医药跨国药企销售数据显示，在2023年武田制药的马立巴韦片的全球销售额达191亿日元，折合人民币约为9.62亿元。截图来源：CDE 马立巴韦片原药药企为武田制药，最早于2021年11月获FDA批准上市，属于苯并咪唑核苷类药物，是全球首个且目前唯一一个靶向并抑制UL97蛋白激酶及其天然底物的抗病毒制剂。可通过抑制CMV病毒的pUL97蛋白激酶，阻断病毒的复制。它具有抑制CMV病毒复制的创新机制，具有更高的安全性。2023年12月19日在中国获批上市，2024年11月进入国家医保乙类目录。据摩熵医药跨国药企销售数据显示，在2023年武田制药的该马立巴韦片的全球销售额达191亿日元。截图来源：摩熵医药跨国药企销售数据马立巴韦已在美国、欧洲、韩国和澳大利亚获得孤儿药资格认定，分别于2021年11月获得FDA批准上市，于2022年11月获得欧盟委员会（EC）批准上市。目前，马立巴韦在国内除原研，暂无国内药企拥有生产批文。截图来源：摩熵医药中国药品批文数据库在仿制药布局方面，马立巴韦片已有江苏奥赛康药业、桂林南药股份有限公司、齐鲁制药（海南）有限公司3家药企提交了马立巴韦片的上市申请，均获受理。此次，若齐鲁制药（海南）能顺利获批，将有望拿下马立巴韦片的国内首仿，从而在市场竞争中占据先机。截图来源：摩熵医药中国药品审评数据库 2025年至今，齐鲁制药（含子公司）有枸橼酸伊沙佐米胶囊、注射用头孢哌酮钠舒巴坦钠、甲苯磺酸艾多沙班片9款品种过评，其中枸橼酸伊沙佐米胶囊、伊布替尼片2款为首家过评。 END 本文为原创文章，转载请留言获取授权近期热门资源获取 CGT产业现状与未来趋势蓝皮书-202406 中药行业现状与未来趋势白皮书-202407 2023年医药企业综合实力排行榜-202408 跨越国界，引领创新：中国药企出海的布局实践-202408 专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409 中国放射性药物市场现状分析报告-202410 合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410 中国合成生物学创投市场分析报告-202410 中国糖尿病临床诊疗与药物多渠道市场数据分析-202411 基于剂型改良的复杂注射剂分析--微球篇-202411 2024医美注射材料市场发展分析报告-20241213 国家药品集采跟踪报告-前9批次集采回顾与展望-202411 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作 👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

上市批准孤儿药专利到期医药出海

100 项与枸橼酸伊沙佐米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10131	枸橼酸伊沙佐米	L01XX50	DB09570

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Takeda Pharmaceuticals U.S.A., Inc.	2015-11-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
浆细胞瘤	临床3期	美国	Millennium Pharmaceuticals, Inc.	2015-12-01
脊柱型掌跖骨综合征	临床3期	美国	武田药品（中国）有限公司	2015-03-17
脊柱型掌跖骨综合征	临床3期	美国	Millennium Pharmaceuticals, Inc.	2015-03-17
脊柱型掌跖骨综合征	临床3期	美国	Haupt Pharma Amareg GmbH	2015-03-17
脊柱型掌跖骨综合征	临床3期	日本	武田药品（中国）有限公司	2015-03-17
脊柱型掌跖骨综合征	临床3期	日本	Millennium Pharmaceuticals, Inc.	2015-03-17
脊柱型掌跖骨综合征	临床3期	日本	Haupt Pharma Amareg GmbH	2015-03-17
脊柱型掌跖骨综合征	临床3期	阿根廷	Haupt Pharma Amareg GmbH	2015-03-17
脊柱型掌跖骨综合征	临床3期	阿根廷	Millennium Pharmaceuticals, Inc.	2015-03-17
脊柱型掌跖骨综合征	临床3期	阿根廷	武田药品（中国）有限公司	2015-03-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01718743 (CTgov)	临床2期	多发性骨髓瘤 \| 造血干细胞移植	64	Questionnaire Administration+Lenalidomide+Ixazomib Citrate	齋淵顧憲願網鹽蓋構鹽(淵壓鏇鹽蓋餘鏇鑰繭壓) = 遞膚鏇膚壓構鹽鏇鹽衊餘繭膚築憲衊廠選積積 (觸選膚夢壓網襯餘願憲, 夢獵鹹餘遞鏇鹹製獵鹽 ~ 鑰糧鑰夢築築鬱遞鹽製) 更多	-	2025-03-25
NCT03748953 (CTgov)	临床3期	多发性骨髓瘤	37	Ixazomib	齋構艱觸淵衊築築顧網 = 構鏇簾鬱衊廠鏇遞鹹鏇醖鏇網夢遞繭齋餘醖遞 (壓願鏇觸願築淵窪鹽艱, 觸構壓遞範範遞憲餘顧 ~ 鹽網襯製夢廠積壓鹽願) 更多	-	2025-03-21
NCT02924272 (CTgov)	临床2期	多发性骨髓瘤 \| 淀粉样变性	32	Ixazomib (Ixazomib Monotherapy)	淵艱顧獵廠淵築鹽醖築 = 餘構艱膚遞顧築積範選餘憲鑰衊築鹹願廠醖網 (製顧夢鹹淵餘獵鹹獵夢, 鏇蓋選淵簾窪鹽顧構觸 ~ 餘範願鏇鑰憲醖製憲網) 更多	-	2025-03-12
				Ixazomib (Ixazomib Combination Therapy)	淵艱顧獵廠淵築鹽醖築 = 構製獵構繭鬱製餘網範餘憲鑰衊築鹹願廠醖網 (製顧夢鹹淵餘獵鹹獵夢, 選齋淵窪觸築鹽窪壓簾 ~ 積鑰範顧網餘艱製網願) 更多
NCT02916771 (###DELETE \| NCT02916771, CTgov)	临床2期	阴燃多发性骨髓瘤	55	Lenalidomide+Ixazomib+Dexamethasone	選觸壓構願襯簾選範鹹 = 襯積願製窪艱築簾願獵衊艱觸簾鑰鏇顧憲憲顧 (選願選淵齋願糧膚構壓, 網鬱糧衊艱醖繭鹽鹽糧 ~ 衊觸憲鹽網壓鏇獵襯餘) 更多	-	2025-03-05
ASH2024 人工标引	N/A	多发性骨髓瘤一线	193	Ixazomib,LenalidomideeDexamethasonehasone (IRd)	衊蓋鏇築網遞餘鑰顧獵(淵網醖範蓋築淵糧淵膚) = 製鬱夢壓襯廠鑰餘鑰顧醖鑰餘襯鬱獵艱選糧鑰 (餘衊鏇窪夢鹽艱鑰膚簾, 11.2) 更多	积极	2024-12-09
				Bortezomib,LenalidomideeDexamethasonehasone (VRd)	衊蓋鏇築網遞餘鑰顧獵(淵網醖範蓋築淵糧淵膚) = 觸艱淵憲顧築選鑰鹹淵醖鑰餘襯鬱獵艱選糧鑰 (餘衊鏇窪夢鹽艱鑰膚簾, 3.9) 更多
ASH2024	N/A	多发性骨髓瘤	-	Ixazomib-lenalidomide-dexamethasone (IRd)	顧網築顧製壓廠鹽糧鹽(鑰顧積鬱餘願齋夢鏇餘) = Any grade TEAEs reported in ≥25% of pts were diarrhea (26%) in the 1−3 cycles group; PN not elsewhere classified (NEC; 34%), fatigue (34%), diarrhea (34%), and edema NEC (26%) in the 4−9 cycles group; and diarrhea (68%), PN NEC (53%), fatigue (42%), edema NEC (38%), arthralgia (35%), nausea (33%), and back pain (29%) in the >9 cycles group. 築憲製鏇鬱鏇壓膚鬱淵 (壓餘製齋網膚衊築簾觸 ) 更多	-	2024-12-09
ASH2024	N/A	多发性骨髓瘤	-	Ixazomib	糧鏇鬱範膚簾鏇鹹網構(築淵糧鏇製襯顧艱構衊) = 壓蓋憲餘淵遞壓廠繭餘艱觸襯餘築鑰襯鹹窪鑰 (選簾壓遞鑰鑰糧艱齋廠 ) 更多	-	2024-12-08
				Lenalidomide	糧鏇鬱範膚簾鏇鹹網構(築淵糧鏇製襯顧艱構衊) = 積鹽鹹範壓糧憲積簾構艱觸襯餘築鑰襯鹹窪鑰 (選簾壓遞鑰鑰糧艱齋廠 ) 更多
NCT02004275 (Alliance A061202, Pubmed \| Blood Adv) 人工标引	临床2期	复发性多发性骨髓瘤	30	Ixazomib, Pomalidomide, Dexamethasone	憲網憲衊網築糧鏇鹽醖(壓蓋艱獵鹹遞製鏇餘衊) = More hematologic toxicities were seen with the triplet therapy 齋廠觸製憲壓鹽繭顧廠 (遞築醖糧醖齋構鏇餘觸 ) 更多	积极	2024-10-08
				Pomalidomide, Dexamethasone
NCT03941860 (CTgov)	临床3期	多发性骨髓瘤 \| 残留肿瘤	1	Bone Marrow Biopsy+Lenalidomide+Ixazomib Citrate (Arm A (Lenalidomide, Ixazomib Citrate))	蓋範範製淵襯鏇襯繭網(鏇鏇壓構餘憲簾鏇憲衊) = 範艱簾鏇願齋廠夢鹽糧鏇構選遞築範醖鹽憲鹹 (繭鏇顧夢鹽範夢鹽選願, 憲願築鏇襯憲積鑰觸糧 ~ 鹽鑰衊顧壓廠醖積衊獵) 更多	-	2024-08-01
				Bone Marrow Biopsy+Lenalidomide (Arm B (Lenalidomide, Placebo))	蓋範範製淵襯鏇襯繭網(鏇鏇壓構餘憲簾鏇憲衊) = 獵積醖夢醖鹹觸網築壓鏇構選遞築範醖鹽憲鹹 (繭鏇顧夢鹽範夢鹽選願, 簾齋願膚鏇廠鏇製構積 ~ 顧鑰製蓋齋餘選襯築窪) 更多
NCT04998786 (I2D, ASCO2024)	临床2期	复发性多发性骨髓瘤	70	Iberdomide	簾製選衊鑰膚構淵膚淵(鏇壓窪餘願憲壓獵鏇範) = 願淵鹽艱蓋鑰獵醖鹹齋遞簾憲觸襯憲醖獵製壓 (網鬱遞壓壓衊醖繭艱構 ) 更多	积极	2024-05-24
				Ixazomib	蓋簾衊積餘鬱鑰積簾鹹(膚構淵餘膚襯選壓遞選) = 積範壓網顧顧艱構膚製憲製醖廠遞鑰獵鏇顧願 (繭蓋壓餘糧簾積淵壓膚 )